Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "June-Key Chung"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
The Relationship between Expression of the Sodium/iodide Symporter Gene and the Status of Hormonal Receptors in Human Breast Cancer Tissue
Hyun Jung Oh, June-Key Chung, Joo Hyun Kang, Won Jun Kang, Dong Young Noh, In Ae Park, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee
Cancer Res Treat. 2005;37(4):247-250.   Published online August 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.4.247
AbstractAbstract PDFPubReaderePub
Purpose

It has been reported that the sodium/iodide symporter (NIS) gene is expressed in several breast cancer tissues, suggesting the possibility of radionuclide imaging and therapy. However, the regulatory mechanism of NIS gene expression in breast cancer is not yet understood. To assess the relationship between the hormonal status and the NIS expression in breast cancer tissue, we investigated the NIS expression and correlated it to the expression of the thyrotropin receptor (thyroid stimulating hormone receptor, TSH-R), the estrogen receptor (ER) and the progesterone receptor (PR) in human breast cancer tissues.

Materials and Methods

Breast cancer tissues were obtained from 44 patients. Pathological examination showed 2 cases of Grade I, 17 of Grade II, 22 of Grade III, and 3 of unknown grade. We measured the expression of NIS and TSH-R genes by using RT-PCR and we measured the status of ER and PR by using immunohistochemistry.

Results

The NIS gene was expressed in 15 (34%) of the 44 breast cancer tissues. The NIS gene was expressed in 32% of the cases with TSH-R gene expression. The NIS gene was expressed in 40% of the breast cancer tissues with a positive PR and in 31% with a negative PR (p>0.05). It was positive for PR in 18% of the cases and negative for PR in 39% of the cases (p>0.05).

Conclusion

The NIS gene is expressed in approximately one-third of the human breast cancer tissues. Its expression was not related to the presence of the TSH-R gene or hormonal receptors, ER and PR.

Citations

Citations to this article as recorded by  
  • Benign thyroid disease and the risk of breast cancer: An updated systematic review and meta-analysis
    Mingyue Han, Yao Wang, Yuanhui Jin, Xue Zhao, Haiying Cui, Guixia Wang, Xiaokun Gang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions
    Man Lu, Hanqing Liu, Bilian Zheng, Shengrong Sun, Chuang Chen
    Cancers.2022; 14(20): 5117.     CrossRef
  • Competitive Endogenous Role of the LINC00511/miR-185-3p Axis and miR-301a-3p From Liquid Biopsy as Molecular Markers for Breast Cancer Diagnosis
    Marwa M. Mahmoud, Eman F. Sanad, Reham A.A. Elshimy, Nadia M. Hamdy
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The correlation between breast cancer and urinary iodine excretion levels
    Fatma Umit Malya, Huseyin Kadioglu, Mustafa Hasbahceci, Kemal Dolay, Mehmet Guzel, Yeliz Emine Ersoy
    Journal of International Medical Research.2018; 46(2): 687.     CrossRef
  • Different expression of sodium–iodide importer (NIS) between lactating breast and thyroid tissues may be due to structural difference of thyroid-stimulating hormone receptor (TSHR)
    X.-Z. Shi, L. Xue, X. Jin, P. Xu, S. Jia, H.-M. Shen
    Journal of Endocrinological Investigation.2017; 40(1): 41.     CrossRef
  • Is there an association between thyroid function abnormalities and breast cancer?
    Anna Angelousi, Evanthia Diamanti-Kandarakis, Evangelia Zapanti, Afroditi Nonni, Eftuxios Ktenas, Aimilia Mantzou, Konstantinos Kontzoglou, Grigorios Kouraklis
    Archives of Endocrinology and Metabolism.2017; 61(1): 54.     CrossRef
  • Iodide transport and breast cancer
    Vikki L Poole, Christopher J McCabe
    Journal of Endocrinology.2015; 227(1): R1.     CrossRef
  • The prognosis and treatment of primary thyroid cancer occurred in breast cancer patients: comparison with ordinary thyroid cancer
    Chang Min Park, Young Don Lee, Eun Mee Oh, Kwan-Il Kim, Heung Kyu Park, Kwang-Pil Ko, Yoo Seung Chung
    Annals of Surgical Treatment and Research.2014; 86(4): 169.     CrossRef
  • Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer
    Salvatore Micali, Stefania Bulotta, Cinzia Puppin, Angelo Territo, Michele Navarra, Giampaolo Bianchi, Giuseppe Damante, Sebastiano Filetti, Diego Russo
    BMC Cancer.2014;[Epub]     CrossRef
  • TSH receptor antibodies have predictive value for breast cancer – retrospective analysis
    Paweł Szychta, Wojciech Szychta, Adam Gesing, Andrzej Lewiński, Małgorzata Karbownik-Lewińska
    Thyroid Research.2013;[Epub]     CrossRef
  • Quantitative Immunohistochemical Analysis Reveals Association between Sodium Iodide Symporter and Estrogen Receptor Expression in Breast Cancer
    Sushmita Chatterjee, Renu Malhotra, Frency Varghese, Amirali B. Bukhari, Asawari Patil, Ashwini Budrukkar, Vani Parmar, Sudeep Gupta, Abhijit De, Pranela Rameshwar
    PLoS ONE.2013; 8(1): e54055.     CrossRef
  • Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer
    Sasha J Beyer, Xiaoli Zhang, Rafael E Jimenez, Mei-Ling T Lee, Andrea L Richardson, Kun Huang, Sissy M Jhiang
    BMC Research Notes.2011;[Epub]     CrossRef
  • Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?
    S. J. Beyer, R. E. Jimenez, C. L. Shapiro, J. Y. Cho, S. M. Jhiang
    Breast Cancer Research and Treatment.2009; 115(1): 205.     CrossRef
  • 11,461 View
  • 64 Download
  • 13 Crossref
Close layer
Usefulness of Additional Delayed Regional F-18 Fluorodeoxy-glucose Positron Emission Tomography in the Lymph Node Staging of Non-Small Cell Lung Cancer Patients
Young So, June-Key Chung, Jae Min Jeong, Dong Soo Lee, Myung Chul Lee
Cancer Res Treat. 2005;37(2):114-121.   Published online April 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.2.114
AbstractAbstract PDFPubReaderePub
Purpose

In this study, we examined whether additional, delayed regional FDG PET scans could increase the accuracy of the lymph node staging of NSCLC patients.

Materials and Methods

Among 87 patients who underwent open thoracotomy or mediastinoscopic biopsy under the suspicion of NSCLC, 35 (32 NSCLC and 3 infectious diseases) who had visible lymph nodes on both preoperative whole body scan and regional FDG PET scan were included. The following 3 calculations were made for each biopsy-proven, visible lymph node: maximum SUV of whole body scan (WB SUV), maximum SUV of delayed chest regional scan (Reg SUV), and the percent change of SUV between WB and regional scans (% SUV Change). ROC curve analyses were performed for WB SUVs, Reg SUVs and % SUV Changes.

Results

Seventy lymph nodes (29 benign, 41 malignant) were visible on both preoperative whole bodyscan and regional scan. The means of WB SUVs, Reg SUVs and % SUV Changes of the 41 malignant nodes, 3.71±1.08, 5.18±1.60, and 42.59±33.41%, respectively, were all significantly higher than those of the 29 benign nodes, 2.45±0.73, 3.00±0.89, and 22.71±20.17%, respectively. ROC curve analysis gave sensitivity and specificity values of 80.5% and 82.8% at a cutoff of 2.89 (AUC 0.839) for WB SUVs, 87.8% and 82.8% at a cutoff of 3.61 (AUC 0.891) for Reg SUVs, and 87.8% and 41.4% at a cutoff of 12.3% (AUC 0.671) for % SUV Changes.

Conclusion

Additional, delayed regional FDG PET scans may improve the accuracy of lymph node staging of whole body FDG PET scan by providing additional criteria of Reg SUV and % SUV Change.

Citations

Citations to this article as recorded by  
  • KSNM60 in Clinical Nuclear Oncology
    Seung Hwan Moon, Young Seok Cho, Joon Young Choi
    Nuclear Medicine and Molecular Imaging.2021; 55(5): 210.     CrossRef
  • 18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and backgro
    Stephen P Povoski, Douglas A Murrey, Sabrina M Smith, Edward W Martin, Nathan C Hall
    BMC Cancer.2014;[Epub]     CrossRef
  • Fluorodeoxyglucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy
    Hyun-Cheol Kang, Hong-Gyun Wu, Tosol Yu, Hak Jae Kim, Jin Chul Paeng
    Radiation Oncology Journal.2013; 31(3): 111.     CrossRef
  • Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting
    Thomas C. Kwee, Sandip Basu, Drew A. Torigian, Babak Saboury, Abass Alavi
    European Journal of Nuclear Medicine and Molecular Imaging.2011; 38(7): 1353.     CrossRef
  • Imaging Atherosclerosis in the Carotid Arteries with F-18-Fluoro-2-deoxy-D-glucose Positron Emission Tomography: Effect of Imaging Time after Injection on Quantitative Measurement
    Minyoung Oh, Ji Young Kim, Kwang-Ho Shin, Seol Hoon Park, Jin-Sook Ryu, Jae Seung Kim, Hye-Jin Kim, Dong-Wha Kang, Dae Hyuk Moon
    Nuclear Medicine and Molecular Imaging.2010; 44(4): 261.     CrossRef
  • 10,155 View
  • 48 Download
  • 5 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP